Product class: Authorized package
Medicinal product class: For human use
Package code: 1667538
Name of medicinal product: CINACALCET ACCORD
Active substances:
Cinacalcet
Estonian, English, Latin
ATC code: H05BX01
Dosage form: film-coated tablet
Route of administration: oral use
Strengh: 30mg
Amount in package: 28TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Secondary hyperparathyroidism Adults Treatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Paediatric population Treatment of secondary hyperparathyroidism (HPT) in children aged 3years and older with end?stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4). may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1). Parathyroid carcinoma and primary hyperparathyroidism in adults Reduction of hypercalcaemia in adult patients with: • parathyroid carcinoma. • primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated 03 March 2021)
Package information leaflet (PIL): EST  (last updated 21 May 2020)
Labelling:  (last updated 20 March 2019)
Last imported to Estonia: 31 October 2023
Marketing authorization holder: Accord Healthcare B.V. 
Marketing authorization number: 892315 
Marketing authorization issued on: 11 November 2015 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Decentralised 
Percent Valid from Valid until Valid Diagnosis Doctor's speciality Primary Age Other
100  05/04/2024     Yes  N18-N18  Pediaater, Nefroloog  No     hemo- või peritoneaaldialüüsil olevatele patsientidele, kelle ravi vitamiin D analoogidega on ebaõnnestunud (seerumi parathormooni taseme eesmärkväärtust <=300 pg/ml ei saavutata) või kellele on vitamiin D analoogid vastunäidustatud 
50  05/04/2024     Yes      No      
100  05/04/2024     Yes  N18-N18  Pediaater, Nefroloog  No  until 4 years  hemo- või peritoneaaldialüüsil olevatele patsientidele, kelle ravi vitamiin D analoogidega on ebaõnnestunud (seerumi parathormooni taseme eesmärkväärtust <=300 pg/ml ei saavutata) või kellele on vitamiin D analoogid vastunäidustatud 
100  05/04/2024     Yes      No  until 4 years   
Reference price: 85.40 EUR 
Under reference price: No 
Reference price of daily dose: 6.10 EUR 
Entry/Changing date: 03 March 2021
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription